Abstract

Methylphenidate (MPD) is commonly prescribed for patients with Attention Deficit/Hyperactivity Disorder (ADHD). Although used off-label, MPD forms part of complex and multifactorial treatment regimen for narcolepsy and hypersomnia, together with including behavioural interventions. The drug is sometimes also prescribed off-label to subjects with other mental illness or somatic condition to improve intellectual outcome, ease fatigue or enhance the ability to concentrate. Common side effects include headache, insomnia, decreased appetite and hypertension. Concurrently, clinicians should be aware of relatively rare but potentially threatening adverse effects including agitation and psychotic symptoms. Several case reports regarding MPD-induced psychosis have been published, but most of them regard children or teenagers (1) and much less is known about drug-induced psychosis in adults (2). In this article, we present a case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient. Careful evaluation including clinical examination, medical and family history and possible early signs of psychosis is recommended each time before MPD treatment will be initiated.

Highlights

  • We present a case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient

  • Careful evaluation including clinical examination, medical and family history and possible early signs of psychosis is recommended each time before MPD treatment will be initiated

  • Methylphenidate (MPD) is a medication commonly prescribed for children and adult patients with Attention Deficit/Hyperactivity Disorder (ADHD) worldwide

Read more

Summary

Introduction

Methylphenidate (MPD) is a medication commonly prescribed for children and adult patients with Attention Deficit/Hyperactivity Disorder (ADHD) worldwide. Prevalence rates of ADHD in Poland are 0.3% in children and adolescents, and 0.8% in adults (1), while worldwide meta-analysis disclose the rates about 16% both in children (3) and adults (4).Such high difference in prevalence rates between

Polish and world data may result from different methodology
Pharmacological properties
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call